What Are Clinical Trials?
[jwplayer mediaid=”1718″]
Stand Up To Cancer – Clinical Trials
Download the Stand Up To Cancer clinical trials (StandUpToCancer.org/ClinicalTrials) campaign toolkit. Thank you for helping to spread the message about the significance of clinical trials new, better treatments for cancer. With this campaign, we want to increase awareness about the importance of clinical trials, and what participation in a clinical trial really means. We hope that increasing understanding about clinical trials will increase participation as patients and caregivers better understand the value of advanced treatment that clinical trials offer and help to advance.
To learn more please go to https://thesocialpresskit.com/clinical-trials
The GALAHAD Study
A clinical research study is now enrolling men who have metastatic castration?resistant prostate cancer and DNA?repair anomalies.
Janssen Research & Development is seeking men to participate in a clinical trial of an oral investigational medication for prostate cancer. All participants will receive daily investigational medication.
To learn more about the Galahad study and find out if you may be eligible, please visit: www.clinicaltrials.gov Study Identifier: NCT02854436
Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
The EMBARK Study
Working to help men in their fight against prostate cancer.
The PROSPER Clinical Trial is a global Phase 3 clinical research trial that will include about 1500 participants. The trial will test the effects of an oral investigational drug called enzalutamide in men with nonmetastatic prostate cancer that continues to progress despite hormonal therapy. The purpose of the PROSPER Clinical Trial is to compare how enzalutamide works when combined with standard treatment vs. the standard treatment only.
To learn more please go to http://www.menshealthnetwork.org/PROSPER-Patient-Pamphlet.pdf And to find the clinical trial click: https://clinicaltrials.gov/ct2/show/NCT02003924
Prostate Cancer Clinical Research Studies – TALAPRO-1 and TALAPRO-2
- TALAPRO-1: A phase 2, open-label study of talazoparib in men with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal therapy (NHT) NCT03148795
- TALAPRO-2: A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) NCT03395197
Learn more on this page: http://www.menshealthresourcecenter.com/clinical-trials/
About clinical research studies
Thousands of volunteers all around the world participate in clinical research studies every year. While they may be motivated to take part for many different reasons, every study participant plays an important role in helping to advance medical knowledge and improve patient care.
Scientists and doctors constantly strive to find different treatment options that may improve the quality of life for those with prostate cancer. It’s only through research that new medicines can be developed and become available to make a difference to people’s lives.
The MAGNITUDE Study
WHY IS THIS CLINICAL RESEARCH STUDY BEING DONE?
The MAGNITUDE Study is a Phase 3 randomized, placebo controlled, double blind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.
AM I ELIGIBLE?
You may be eligible to participate in this study if you:
* Are a male, age 18 or older
* Have a diagnosis of metastatic prostate cancer (which means that cancer has spread to other parts in your body such as bones, liver or lung)
* Are willing to provide a blood sample and tumor tissue sample as part of the study
Before you participate in this study, a detailed description of the study, as well as possible risks and benefits, will be provided in writing in an “informed consent document” and discussed with you. You will be asked to review and sign the informed consent document prior to participating. Your medical history will be reviewed, and you will be given a study required medical exam and have study required laboratory tests such as blood draws.
STUDY DESIGN
The purpose of the study is to compare a combination of the investigational medicine to standard treatment versus a combination of placebo and standard treatment for the treatment of patients with metastatic prostate cancer. A placebo is an inactive treatment, sometimes referred to as a “sugar pill,” that will be provided as capsules and will match the investigational medicine in size, weight, color, shape, and taste.
Once enrolled in the study, feel free to discuss your investigational medication with the study doctor or research staff at any time during the study. Information collected during a clinical research study may or may not ultimately lead to the investigational medicine(s) being approved by regulatory health authorities.
Your participation in the study is voluntary and you can leave the study at any time. Compensation for time and travel may be available.
To learn more about this study and to find out if you may be eligible and if the study is being conducted at a site near you, please visit:
https://clinicaltrials.gov/ct2/show/NCT03748641?term=NCT03748641&rank=1